The Accelerating Medicines Partnership® Heart Failure Program (AMP® HF) is focused on a major unmet need in cardiovascular health. AMP HF brings together partners from the public, private, and nonprofit sectors to investigate the syndrome of heart failure with preserved ejection fraction (HFpEF), which continues to stymie researchers and clinicians. Using cutting-edge technologies, including digital measurements and artificial intelligence analytic methods, AMP HF aims to change the landscape of heart failure treatment paradigms through refinement of HFpEF classification and discovery of improved, more precise treatment options, thus improving the outlook for millions of patients around the world.

The Accelerating Medicines Partnership® (AMP®) Program was launched in February 2014 to bring together the resources and expertise of both the National Institutes of Health (NIH) and the private sector to solve pressing challenges in various diseases and disease areas. The AMP program, managed by the FNIH, is comprised of projects with a common goal of accelerating the process of bringing new and effective therapies to patients and operates under the broad principle of delivering pre-competitive advancements to the research and medical fields to enable broad access and use of AMP research discoveries. Originally focused on three specific diseases, the program has since grown to 10 individual projects representing the contributions and participation of 16 NIH institutes and over 70 private sector partners.

This inaugural scientific symposium celebrated the 10th anniversary of the program, highlighted successful innovation and collaboration in each of the individual AMP project areas, and provided a forum for discussions and cross-collaboration in the broader AMP research community.

https://fnih.org/our-programs/acceler...